Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …

Malignant transformation is characterized by dysregulation of diverse cellular processes that
have been the subject of detailed genetic, biochemical, and structural studies, but only …

High-grade serous ovarian carcinoma (HGSOC) is the most aggressive type of ovarian
cancer, often diagnosed at advanced stages. Molecularly, HGSOC shows high degree of …

The human genome contains regulatory elements, such as enhancers, that are often rewired
by cancer cells for the activation of genes that promote tumorigenesis and resistance to …

Ovarian cancer therapy has remained fundamentally unchanged for 50 years, with surgery
and chemotherapy still the frontline treatments. Typically asymptomatic until advanced …

Ovarian cancer remains the most lethal gynecologic malignancy. We analyzed the
mutational landscape of 64 primary, 41 metastatic, and 17 recurrent fresh-frozen tumors from …

Background Bromodomain and extra-terminal (BET) proteins are epigenetic readers that
bind to acetylated lysines of histones and regulate gene transcription. BET protein family …

The bromodomain and extra-terminal domain (BET) protein BRD4 is emerging as a potential
target for cancer therapy. However, BRD4 roles in regulating the stemness of gastric cancer …

Metabolic reprogramming is an emerging hallmark of cancer and is driven by abnormalities
of oncogenes and tumor suppressors. Accelerated metabolism causes cancer cell …

Ovarian cancer is the second most common gynecologic malignancy in the United States
and the most common cause of gynecologic cancer–related death. The majority of ovarian …